Journal Article Research Support, N.I.H., Extramural Ppublish 1 citation
PubMed: 37516401 DOI: 10.1016/j.ajog.2023.07.042
Addressing a broken drug pipeline for preterm birth: why early preterm birth is an orphan disease.
Am J Obstet Gynecol 229(6):647-655
Authors: Carly Baxter, Isabelle Crary, Brahm Coler, Lauren Marcell, Emily M Huebner, Sara Rutz, Kristina M Adams Waldorf
Affiliations
- School of Medicine, University of Washington, Seattle, WA.
- Elson S. Floyd College of Medicine, Washington State University, Spokane, WA.
- Departments of Obstetrics and Gynecology and Global Health, University of Washington, Seattle, WA.
Abstract
Preterm birth remains one of the most urgent unresolved medical problems in obstetrics, yet only 2 therapeutics for preventing preterm birth have ever been approved by the United States Food and Drug Administration, and neither remains on the market. The recent withdrawal of 17-hydroxyprogesterone caproate (17-OHPC, Makena) marks a new but familiar era for obstetrics with no Food and Drug Administration-approved pharmaceuticals to address preterm birth. The lack of pharmaceuticals reflects a broad and ineffective pipeline hindered by extensive regulatory hurdles, soaring costs of performing drug research, and concerns regarding adverse effects among a particularly vulnerable population. The pharmaceutical industry has historically limited investments in research for diseases with similarly small markets, such as cystic fibrosis, given their rarity and diminished projected financial return. The Orphan Drug Act, however, incentivizes drug development for "orphan diseases", defined as affecting <200,000 people in the United States annually. Although the total number of preterm births in the United States exceeds this threshold annually, the early subset of preterm birth (<34 weeks' gestation) would qualify, which is predominantly caused by inflammation and infection. The scientific rationale for classifying preterm birth into early and late subsets is strong given that their etiologies differ, and therapeutics that may be efficacious for one subset may not work for the other. For example, antiinflammatory therapeutics would be expected to be highly effective for early but not late preterm birth. A robust therapeutic pipeline of antiinflammatory drugs already exists, which could be used to target spontaneous early preterm birth, in combination with antibiotics shown to sterilize the amniotic cavity. New applications for therapeutics targeting spontaneous early preterm birth could categorize as orphan disease drugs, which could revitalize the preterm birth therapeutic pipeline. Herein, we describe why drugs targeting early preterm birth should qualify for orphan status, which may increase pharmaceutical interest for this vitally important obstetrical condition.
MeSH
Gynecology, Infections, Fetus, Pregnancy, Pharmaceutical Preparations, Bronchopulmonary Dysplasia, Therapeutics, Premature Birth, Parturition, Research, Infant, Newborn, Obstetrics, Obstetric Labor, Premature, 17-Alpha-Hydroxyprogesterone, United States Food And Drug Administration